Antitumor Effect of a Generation 4 Polyamidoamine Dendrimer/Cyclooxygenase-2 Antisense Oligodeoxynucleotide Complex on Breast Cancer<i>In Vitro</i>and<i>In Vivo</i>

Xin, Guohong; Zhao, Xinhan; Duan, Xinlei; Ning, Qian; Meng, Min; Du, Min; Liu, Lifeng

doi:10.1089/cbr.2011.1028

Cited by 9 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this experiment combined with those of previous studies [8, 49, 50] indicated that the early growth response gene-1 DNA enzyme was mainly located in the media and adventitia of the vein graft 1 h after grafting and then gradually shifted to the media. There was a small amount of EDRz in the media of the vein graft 3 d after grafting and was mainly located in the media.…”

Section: Discussionsupporting

confidence: 77%

Transfected Early Growth Response Gene-1 DNA Enzyme Prevents Stenosis and Occlusion of Autogenous Vein GraftIn Vivo

Wang

Cheng

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

The aim of this study was to detect the inhibitory action of the early growth response gene-1 DNA enzyme (EDRz) as a carrying agent by liposomes on vascular smooth muscle cell proliferation and intimal hyperplasia. An autogenous vein graft model was established. EDRz was transfected to the graft vein. The vein graft samples were obtained on each time point after surgery. The expression of the EDRz transfected in the vein graft was detected using a fluorescent microscope. Early growth response gene-1 (Egr-1) mRNA was measured using reverse transcription-PCR and in situ hybridization. And the protein expression of Egr-1 was detected by using western blot and immunohistochemistry analyses. EDRz was located at the media of the vein graft from 2 to 24 h, 7 h after grafting. The Egr-1 protein was mainly located in the medial VSMCs, monocytes, and endothelium cells during the early phase of the vein graft. The degree of VSMC proliferation and thickness of intima were obviously relieved compared with the no-gene therapy group. EDRz can reduce Egr-1 expression in autogenous vein grafts, effectively restrain VSMC proliferation and intimal hyperplasia, and prevent vascular stenosis and occlusion after vein graft.

show abstract

Section: Discussionsupporting

confidence: 77%

Transfected Early Growth Response Gene-1 DNA Enzyme Prevents Stenosis and Occlusion of Autogenous Vein GraftIn Vivo

Wang

Cheng

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Dendrimers may play drug carrier roles in nanometer dimensions and efficiently exhibit targeting ligands on their surface due to their nanoscale and multifunctional structure [ 94 , 95 ]. Dendrimers provide an attractive synthetically targeted multivalent system for therapy in cancers and cardiovascular diseases [ 96 , 97 ]. The multivalent dendrimers can be formed by (i) assembly of functionalized components and the formation of the polymer backbone or (ii) reaction after the polymer scaffold has been assembled.…”

Section: Multivalent Nanoconstructs For Targeted Drug Deliverymentioning

confidence: 99%

Critical parameters for design and development of multivalent nanoconstructs: recent trends

Bakshi

Haider

Tiwari

et al. 2022

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Graphical abstract A century ago, the groundbreaking concept of the magic bullet was given by Paul Ehrlich. Since then, this concept has been extensively explored in various forms to date. The concept of multivalency is among such advancements of the magic bullet concept. Biologically, the concept of multivalency plays a critical role in significantly huge numbers of biochemical interactions. This concept is the sole reason behind the higher affinity of biological molecules like viruses to more selectively target the host cell surface receptors. Multivalent nanoconstructs are a promising approach for drug delivery by the active targeting principle. Designing and developing effective and target-specific multivalent drug delivery nanoconstructs, on the other hand, remain a challenge. The underlying reason for this is a lack of understanding of the crucial interactions between ligands and cell surface receptors, as well as the design of nanoconstructs. This review highlights the need for a better theoretical understanding of the multivalent effect of what happens to the receptor–ligand complex after it has been established. Furthermore, the critical parameters for designing and developing robust multivalent systems have been emphasized. We have also discussed current advances in the design and development of multivalent nanoconstructs for drug delivery. We believe that a thorough knowledge of theoretical concepts and experimental methodologies may transform a brilliant idea into clinical translation.

show abstract

“…However, with the use of nanoparticles, diagnostics and therapeutics could be greatly improved for certain types of tumors, such as those tumors currently treated with toxic drugs—i.e. lung (Upadhyay et al 2012) or breast cancer (Xin et al 2012)—or gene therapy—ovarian (Fathabadi et al 2012) and brain cancer (Liu et al 2012). For instance, researchers at the University of Melbourne (Australia) are using certain engineered nanostructures (polymers, micelles and polymersomes) as carriers to deliver drugs that target cancer cells causing minimal biological side effects (Kamphuis et al 2010, Shimoni et al 2012).…”

Section: Introductionmentioning

confidence: 99%

Nanoinformatics knowledge infrastructures: bringing efficient information management to nanomedical research

et al. 2013

View full text Add to dashboard Cite

Nanotechnology represents an area of particular promise and significant opportunity across multiple scientific disciplines. Ongoing nanotechnology research ranges from the characterization of nanoparticles and nanomaterials to the analysis and processing of experimental data seeking correlations between nanoparticles and their functionalities and side effects. Due to their special properties, nanoparticles are suitable for cellular-level diagnostics and therapy, offering numerous applications in medicine, e.g. development of biomedical devices, tissue repair, drug delivery systems and biosensors. In nanomedicine, recent studies are producing large amounts of structural and property data, highlighting the role for computational approaches in information management. While in vitro and in vivo assays are expensive, the cost of computing is falling. Furthermore, improvements in the accuracy of computational methods (e.g. data mining, knowledge discovery, modeling and simulation) have enabled effective tools to automate the extraction, management and storage of these vast data volumes. Since this information is widely distributed, one major issue is how to locate and access data where it resides (which also poses data-sharing limitations). The novel discipline of nanoinformatics addresses the information challenges related to nanotechnology research. In this paper, we summarize the needs and challenges in the field and present an overview of extant initiatives and efforts.

show abstract

Antitumor Effect of a Generation 4 Polyamidoamine Dendrimer/Cyclooxygenase-2 Antisense Oligodeoxynucleotide Complex on Breast CancerIn VitroandIn Vivo

Cited by 9 publications

References 44 publications

Transfected Early Growth Response Gene-1 DNA Enzyme Prevents Stenosis and Occlusion of Autogenous Vein GraftIn Vivo

Transfected Early Growth Response Gene-1 DNA Enzyme Prevents Stenosis and Occlusion of Autogenous Vein GraftIn Vivo

Critical parameters for design and development of multivalent nanoconstructs: recent trends

Nanoinformatics knowledge infrastructures: bringing efficient information management to nanomedical research

Contact Info

Product

Resources

About